Zydus Lifesciences Limited DCF Valuation
ZYDUSLIFE · Healthcare · Current price ₹1,123
Zydus Lifesciences Limited cash-flow valuation
Our discounted cash flow (2-stage) values Zydus Lifesciences Limited at ₹355 per share. Intrinsic value from 2-stage discounted cash flows (primary for asset-light / normal businesses); FCFE path. It carries 70% of the weight in our published estimate of ₹1,348. A discounted cash flow is only as good as the cash-flow path it assumes, so the assumptions behind it are listed in full below.
Try your own assumptions
Prefer to build the discounted cash flow yourself? The DCF calculator below opens pre-filled with Zydus Lifesciences Limited's reported free cash flow, net debt and share count, so you can set your own growth and discount rate.
How we got this fair value
Every number below is part of the same estimate for Zydus Lifesciences Limited. Nothing here is a target price or a forecast of where the share price will go.
The inputs are thin or the models disagree sharply. This is our least reliable kind of estimate, so read the range rather than the single number.
Estimate range ₹674 – ₹2,341
Why this method for this business
The DCF model is appropriate for a pharmaceutical company with a durable moat and predictable cash flows, while the relative PE model captures market sentiment and peer valuation dynamics.
The models behind the number
These methods disagree materially, so the estimate is their plain midpoint rather than a weighted blend. The disagreement is itself the finding.
Intrinsic value from 2-stage discounted cash flows (primary for asset-light / normal businesses); FCFE path
- ev_ebitda is not used due to lack of reliable EBITDA multiples for the sector and the company's unique capital structure
What was missing
- Lack of detailed EBITDA multiples for peer companies
- Limited analyst coverage for precise valuation
- Uncertainty around long-term growth rates
What drives it
27 inputs, grouped by how strong each claim is
- FCF_0 (normalized)
- 1,351 ₹cr
- Net debt
- 11,640.8 ₹cr
- Sector-median P/E
- 38.07×
- Peers used
- 17
- EPS (TTM)
- 44.94 ₹/share
- Own-history median P/E
- 19.71×
fcf_norm (median ≤5y positive)
total_debt − cash
peer-median
peer-median
computed
reconstructed (one feature, dampened — not a cap)
- Discount rate (r)
- 13.28%
- Beta
- 0.85
COE (building-block)
bottom-up industry
- Stage-1 start growth
- 18.59%
- Fade shape
- linear
- Terminal growth (g)
- 5.5%
- Stage-1 years
- 14 y
pat_cagr_5y
lifecycle Growth
macro terminal × quality premium
lifecycle Growth horizon
- Lifecycle stage
- Growth
- Quality premium
- 1.1×
- Term: quality
- +1.6%
- Term: growth
- +30.1%
- Term: capital_allocation
- +12.3%
- Term: financial_strength
- +6.5%
- Term: history
- -14.5%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
forecast engine (L20)
moat Wide + capital allocation
quality 58/100 (about average) → neutral
durable ~16% CAGR (ROCE 16% > hurdle) → premium
capital allocation: rising ROCE funded by strong FCF → premium
financial strength: low leverage (D/E 0.3) → mild premium
history: market paid -48% vs sector, dampened ×0.3 (one feature, not the anchor)
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Path
- FCFE
- Terminal-value fraction
- 0.436
- Premium vs sector
- +36.8%
- Fair-multiple confidence
- 79%
- Fair P/E
- 52.09×
computed (D/E vs 0.8)
PV_TV / (PV_1+PV_TV)
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Zydus Lifesciences Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyMore on Zydus Lifesciences Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.